Document is current
Any future updates will be listed below
-
Authors
Park, Junsik https://orcid.org/0000-0003-4094-2097
Lee, Jung Bok
Lim, Myong Cheol
Kim, Byoung-Gie
Kim, Jae-Weon
Kim, Sunghoon
Choi, Chel Hun
Kim, Hee Seung
Park, Sang Yoon
Lee, Jung-Yun https://orcid.org/0000-0001-7948-1350
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03899610 at ClinicalTrials.govnct02498600 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
https://doi.org/10.1136/jitc-2023-007444
nct03699449 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
https://doi.org/10.1136/jitc-2023-007444
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
nct03899610 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
https://doi.org/10.1136/jitc-2023-007444
nct03249142 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
https://doi.org/10.1136/jitc-2023-007444
nct05605535 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
https://doi.org/10.1136/jitc-2023-007444
Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.
https://doi.org/10.1200/jco.2024.42.16_suppl.5569
Immune features of ovarian tumors with a good response to neo-adjuvant chemotherapy in combination with an anti-PD-L1 alone or with an anti-CTLA4: Data from the randomized IneOV trial (a GINECO study).
https://doi.org/10.1200/jco.2023.41.16_suppl.5586
nct05446870 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
https://doi.org/10.1136/jitc-2023-007444
Documents that mention this clinical trial
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
https://doi.org/10.1136/jitc-2023-007444
-
Funding
Funding for this research was provided by:
AstraZeneca (N/A)
National Research Foundation of Korea (NRF-2021R1A2C1093502)
Yonsei University College of Medicine (6-2021-0115)
- License Information
